Hypothalamic Subregion Abnormalities Are Related to Body Mass Index in Patients with Sporadic Amyotrophic Lateral Sclerosis.
Liu Shuangwu,Ren Qingguo,Gong Gaolang,Sun Yuan,Zhao Bing,Ma Xiaotian,Zhang Na,Zhong Suyu,Lin Yan,Wang Wenqing,Zheng Rui,Yu Xiaolin,Yun Yan,Zhang Dong,Shao Kai,Lin Pengfei,Yuan Ying,Dai Tingjun,Zhang Yongqing,Li Ling,Li Wei,Zhao Yuying,Shan Peiyan,Meng Xiangshui,Yan Chuanzhu
DOI: https://doi.org/10.1007/s00415-021-10900-3
2021-01-01
Journal of Neurology
Abstract:OBJECTIVE:To investigate atrophy patterns in hypothalamic subunits at different stages of ALS and examine correlations between hypothalamic subunit volume and clinical information.METHODS:We used the King's clinical staging system to divide 91 consecutive ALS patients into the different disease stages. We investigated patterns of hypothalamic atrophy using a recently published automated segmentation method in ALS patients and in 97 healthy controls. We recorded all subjects' demographic and clinical information.RESULTS:Compared with healthy controls, we found significant atrophy in the bilateral anterior-superior subunit and the superior tubular subunit, as well as a reduction in global hypothalamic volume in ALS patients. When we used the King's clinical staging system to divide patients into the different disease stages, we found neither global nor specific subunit atrophy until King's stage 3 in the hypothalamus. Moreover, specific subunit volumes were significantly associated with body mass index.CONCLUSIONS:In a relatively large sample of Chinese patients with ALS, using a recently published automated segmentation method for the hypothalamus, we found the pattern of hypothalamic atrophy in ALS patients differed greatly across King's clinical disease stages. Moreover, specific hypothalamic subunit atrophy may play an important role in energy metabolism in ALS patients. Thus, our findings suggest that hypothalamic atrophy may have potential phenotypic associations, and improved energy metabolism may become an important component of individualised therapy for ALS.